web logo
  • Therapies
    • DNX-2401
    • Combination Therapies
  • Diseases
    • Adult Brain Cancer
    • Pediatric Brain Cancer
  • Clinical Trials
    • Pediatric Clinical Trials
    • Adult Clinical Trials
    • Compassionate Use
  • Company
    • Management Team
    • Board of Directors
    • Key Advisors
    • Clinical Partners
  • Investor Resources
    • Company News & Presentations
    • Scientific Publications
    • Investor Presentations
  • Contact

Clinical News and Investor Resources

Thought Leadership

Treating diffuse midline gliomas with an oncolytic virus

Results from a phase 1 clinical trial of the oncolytic virus DNX-2401, report successful intratumoral…

Read more

The Common Cold as Cure?

As the nation mourns U.S. Sen. John McCain, TMC News is reposting this month’s story about a…

Read more

Convergence of technology, immunotherapy and courage help U of M patient rise above life-threatening brain tumor

In May 2018, 29-year-old Burnsville, MN, resident, Adam Donahue, began experiencing unusual symptoms. “I had…

Read more
< 1 2 3

Clinical Trials Updates

CPRIT Provides $10.8M Grant to Advance B...

September 22, 2025

The oncolytic virus Delta-24-RGD elicits...

June 13, 2025

Oncolytic Adenovirus and Tumor-Targeting...

June 13, 2025

Localized Treatment with Oncolytic Adeno...

June 13, 2025

Preclinical Characterization of the Anti...

June 13, 2025

Examination of the Therapeutic Potential...

June 13, 2025

See More Content
footer-logo
  • Address

    3400 Edloe Street, Suite 335 Houston, TX 77027

Therapies
  • DNX-2401 (tasadenoturev)
  • Combination Therapies
Diseases
  • Adult Brain Cancer
  • Pediatric Brain Cancer
Science
  • Pediatric Clinical Trials
  • Adult Clinical Trials
Company
  • Management Team
  • Board of Directors
  • Clinical Partners
Contact
  • Terms of Use Policy
  • Privacy Policy

Copyright © 2026. CVBio. All Rights Reserved